Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Girmay Asgedom"'
Autor:
Tammey J. Naab, Anita Gautam, Luisel Ricks-Santi, Ashwini K. Esnakula, Yasmine M. Kanaan, Robert L. DeWitty, Girmay Asgedom, Khepher H. Makambi, Massih Abawi, Jan K. Blancato
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-7 (2018)
Abstract Background MYC overexpression is associated with poor prognosis in breast tumors (BCa). The objective of this study was to determine the prevalence of MYC amplification and associated markers in BCa tumors from African American (AA) women an
Externí odkaz:
https://doaj.org/article/d8b32221a3c04055bc126f1606eaf5d7
Autor:
Martin F. Lavin, Girmay Asgedom, Axel Schambach, Thilo Dörk, Kristine Bousset, Anna Vatselia, Lea Völkening, Holger Bastians, Detlev Schindler
Publikováno v:
The FASEB Journal. 34:2812-2820
The Mre11A/RAD50/NBN complex (MRN) is an essential regulator of the cellular damage response after DNA double-strand breaks (DSBs). More recent work has indicated that MRN may also impact on the duration of mitosis. We show here that RAD50-deficient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05576529e6ca73c6d2f19c60b9e36262
https://doi.org/10.1096/fj.201902318r
https://doi.org/10.1096/fj.201902318r
Autor:
Robert L. DeWitty, Khepher H. Makambi, Ashwini Esnakula, Anita Gautam, Jan Blancato, Luisel Ricks-Santi, Yasmine Kanaan, Tammey Naab, Girmay Asgedom, Massih Abawi
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-7 (2018)
BMC Cancer
BMC Cancer
Background MYC overexpression is associated with poor prognosis in breast tumors (BCa). The objective of this study was to determine the prevalence of MYC amplification and associated markers in BCa tumors from African American (AA) women and determi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4d4b5858f6960ada073cdf5d852ed2d
http://link.springer.com/article/10.1186/s12885-018-4171-6
http://link.springer.com/article/10.1186/s12885-018-4171-6
Publikováno v:
Haematologica. 88(11)
Early treatment response is a strong predictor for treatment outcome in childhood acute lymphoblastic leukemia (ALL), treated within the protocols of the Berlin-Frankfurt-Münster (BFM) study group. In the ALL-BFM trials, early treatment response is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::cb311411fb959274b50ace8791135b8c
https://pubmed.ncbi.nlm.nih.gov/14607754
https://pubmed.ncbi.nlm.nih.gov/14607754
Publikováno v:
Haematologica. 88(3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a5755c7501ab92abe7fd97ad440861fc
https://pubmed.ncbi.nlm.nih.gov/12651279
https://pubmed.ncbi.nlm.nih.gov/12651279